Detalles de la búsqueda
1.
Real-world management patterns in EGFR-mutant advanced non-small-cell lung cancer before first-line adoption of osimertinib: the REFLECT study in Greece.
Future Oncol
; 18(28): 3151-3164, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35929414
2.
Clinical Outcomes Beyond 1L EGFR-TKI Progression in mNSCLC: Final Results of the Real-World Study 'LUNGFUL'.
Anticancer Res
; 43(5): 2243-2258, 2023 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-37097667
3.
A Real-World, Observational, Prospective Study to Assess the Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations upon Progression on or after First-Line Therapy with a First- or Second-Generation EGFR Tyrosine Kinase Inhibitor in EGFR Mutation-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer: The 'LUNGFUL' Study.
Cancers (Basel)
; 13(13)2021 Jun 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-34202063
Resultados
1 -
3
de 3
1
Próxima >
>>